<DOC>
	<DOCNO>NCT01575782</DOCNO>
	<brief_summary>Chloroquine make tumor cell less resistant chemo/radiotherapy . In trial chloroquine give radiotherapy . The dose increase cohort least 3 patient .</brief_summary>
	<brief_title>Chloroquine Anti-autophagic Radiosensitizing Drug Stage I-III Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Histologically cytologically confirm stage IIII small cell lung cancer , exclude malignant pleural/pericardial effusion . At least one measurable disease site , define lesion ≥ 1 cm unidimensionally CTscan WHO performance status 02 Absolute neutrophil count least 1800/µl platelet least 100000/µl hemoglobin least 6.2 mmol/l . Adequate renal function : calculated creatinine clearance least 60 ml/min Adequate hepatic function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) institution ; ALT , AST , alkaline phosphatase ≤ 2.5 x ULN institution ( case liver metastases ≤ 5 x ULN institution ) No previous platinum chemotherapy topoisomeraseinhibitors SCLC . Lung function : FEV1 least 30 % DLCO least 30 % age predict value No history prior chest radiotherapy Life expectancy 6 month Willing able comply study prescription 18 year old Not pregnant breast feeding willing take adequate contraceptive measure study Ability give give write informed consent patient registration No mixed pathology , e.g . nonsmall cell plus small cell cancer No recent ( &lt; 3 month ) severe cardiac disease ( NYHA class &gt; 1 ) ( congestive heart failure , infarction ) No history cardiac arrythmia ( multifocal premature ventricular contraction , uncontrolled atrial fibrillation , bigeminy , trigeminy , ventricular tachycardia ) symptomatic require treatment ( CTC AE 3.0 ) , asymptomatic sustain ventricular tachycardia . Asymptomatic atrial fibrillation control medication allow . No cardiac conduction disturbance medication potentially cause : QTc interval prolongation medication require discontinuation treatment Congenital long QTsyndrome unexplained sudden death first degree relative 40 year age QT interval &gt; 480 msec ( note : case screen ECG , ECG may repeat twice . If average QTinterval 3 measurement remain 480 msec , patient eligible ) Patients medication potentially prolongating QTinterval exclude QTinterval &gt; 460 msec ( Appendix , table 2 ) . Medication might cause QTprolongation Torsades de pointes tachycardia allow ( Appendix , Table 1 ) . Drugs risk prolongating QTinterval discontinue allow , however , close monitoring treat physician ( Appendix , table 2 ) . Complete leave bundle branch block No uncontrolled infectious disease No active malignancy No major surgery ( exclude diagnostic procedure like e.g . mediastinoscopy ) previous 4 week No treatment investigational drug 4 week prior study No chronic systemic immune therapy No know G6PD deficiency Patients must psoriasis porphyria . No known hypersensitivity 4aminoquinoline compound . Patients must retinal visual field change prior 4aminoquinoline compound use . No known prior hypersensitivity cisplatin , etoposide chloroquine component . The opposite</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>small cell lung cancer</keyword>
	<keyword>stage I-III</keyword>
	<keyword>chloroquine</keyword>
	<keyword>Phase I</keyword>
</DOC>